Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator

Area of Science:

• Cardiology
• Metabolomics
• Biomarker Discovery

Background:

• Implantable cardioverter defibrillators (ICDs) are crucial for preventing sudden cardiac death (SCD) in patients with life-threatening ventricular arrhythmias (LTVA).
• Current patient selection and risk stratification methods for ICDs are suboptimal, necessitating improved diagnostic tools.

Purpose of the Study:

• To investigate whether specific metabolites in plasma are associated with LTVA in patients undergoing ICD implantation.
• To identify potential novel biomarkers for LTVA risk stratification using metabolomics.

Main Methods:

• Plasma samples were collected from 72 patients receiving ICDs.
• Metabolomic profiling was performed to analyze metabolite concentrations.
• Statistical analysis, including adjustment for confounding factors and pathway analysis, was used to identify associations with LTVA events.

Main Results:

• Twenty-three metabolites were significantly associated with LTVA after adjusting for clinical risk factors.
• Pathway analysis indicated disrupted metabolism of amino acids, including glycine, serine, threonine, and branched-chain amino acids, in patients experiencing LTVA.
• A panel of 6 metabolites demonstrated potential predictive value for LTVA, achieving an area under the receiver operating characteristic curve of 0.8.

Conclusions:

• Metabolomic profiling can identify dysregulated metabolites associated with LTVA in patients with ICDs.
• Specific metabolic pathways and a panel of 6 metabolites show promise as biomarkers for LTVA risk.
• Further research is warranted to elucidate biological mechanisms and explore clinical utility for improved ICD patient management.